Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma

Talquetamab is injected under the skin (subcutaneously injected) by trained medical staff. During first cycle of talquetamab, the dose of talquetamab will increase until the goal dose (treatment dose) is reached (pre-determined dose escalation).

Administered orally once per day (days 1-21 of applicable 28-day cycles; Days 1-7 of the 7-day Cohort B pre-phase cycle).

Administered orally once per day, at the schedule outlined in the Arm Descriptions.